Choosing and evaluation of chemotherapy regimens in multimodality therapy of triple negative breast cancer          XU Bing-he. Breast Disease Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021，China
Abstract    Triple negative (estrogen receptor, progesterone receptor and HER-2 are all negative) breast cancer (TNBC), a subgroup of breast cancer, has distinct biological, clinical and pathologic characteristics. TNBC is sensitive to chemotherapy which is main therapeutic method for early and metastatic TNBC. Taxanes or platinum-based chemotherapy may be more effective for TNBC. However, there are still no standard chemoterapeutic regimens. In recent years, target agents have become hotspot of study and direction of future study.